Methadone: The renaissance

Journal of Palliative Care

Volumn 17, Issue 2, 2001, Pages 117-120

  Watanabe, Sharon ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT;

ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; HUMAN; PAIN; PALLIATIVE THERAPY; RAT; REVIEW; SAFETY;

ANALGESICS, OPIOID; ANIMALS; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHADONE; PAIN; PALLIATIVE CARE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0035378789     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585970101700208     Document Type: Review

References (42)

1. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109-115.
2. Gannon C. The use of methadone in the care of the dying. Eur J Palliat Care 1997; 4: 152-158.
3. Eddy NB, Halbach H, Braenden OJ. Synthetic substances with morphine-like effect. Bull World Health Organ 1957; 17: 569-863.
4. Dole VP, Nyswander M. A medical treatment for diacetyl-morphine (heroin) addiction. JAMA 1965; 193: 80-84.
5. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and orally and parenterally administered methadone. Clin Pharmacol Ther 1967; 8: 415-426.
6. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923-930.
7. Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand 1982; 74 (suppl): 66-69.
8. Dole VP, Kreek MJ. Methadone plasma level: sustained by a reservoir of drug in tissue. Proc Natl Acad Sci 1973; 70: 10.
9. Olsen GD. Methadone binding to human plasma proteins. Clin Pharmacol Ther 1973; 14: 338-343.
10. Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of d,l-methadone in man and in the rat. J Med Chem 1971; 14: 194-197.
11. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18: 180-190.
12. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 1972; 13: 633-637.
13. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of metha-done in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392-401.
14. Symonds P. Methadone and the elderly. Br Med J 1977; 1: 512.
15. Twycross RG. A comparison of diamorphine with cocaine and methadone. Br J Clin Pharmacol 1977; 4: 691-693.
16. Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacological considerations in the use of methadone in cancer patients. Cancer Treat Rep 1979; 63: 457-459.
17. Sawe J, Hansen J, Ginman C, Hartvig P, Jakobsson PA, Nilsson MI, et al. Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J 1981; 282: 771-773.
18. Paalzow L, Nilsson L, Stenberg P. Pharmacokinetic basis for optimal methadone treatment of pain in cancer patients. Acta Anaesthesiol Scand 1982; 74: 55-58.
19. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313-322.
20. Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, De Conno F. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986; 1: 203-207.
21. Galer BS, Coyle N, Pastemak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87-91.
22. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer 1993; 72: 2266-2272.
23. Morley JS, Watt JWG, Wells JC, Miles JB. Methadone in pain uncontrolled by morphine. Lancet 1993; 342: 1243.
24. Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994; 8: 153-155.
25. Sjogren P, Jensen N, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59: 313-316.
26. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995; 62: 141-145.
27. De Stoutz N, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378-384.
28. Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995; 10: 315-317.
29. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996; 67: 115-119.
30. Rimmer T, Trotman I. Methadone restores opioid sensitivity in cancer pain. Palliat Med 1996; 10: 58.
31. Watanabe S, Belzile M, Kuehn N, Hanson J, Bruera E. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Cancer Treat Rev 1996; 22(suppl.A): 131-136.
32. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997; 70: 99-101.
33. Fitzgibbon DR, Ready LB. Intravenous high-dose metha-done administered by patient-controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997; 73: 259-261.
34. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. Cancer 1996; 78: 852-857.
35. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998; 82: 1167-1173.
36. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose? J Clin Oncol 1998; 16: 3216-3221.
37. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996; 14: 2836-2842.
38. Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home. J Clin Oncol 1998; 16: 3656-3661.
39. Ebert B, Anderson S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187: 165-168.
40. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997; 223: 5-8.
41. Davis A, Inturrisi CE. d-methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999; 289: 1048-1053.
42. Makin MK, O'Donnell V, Skinner JM, Ellershaw JE. Methadone in the management of cancer related neuropathic pain: report of five cases. Pain Clin 1998; 10: 275-279.